EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation

Neuro-Oncology

Volumn 18, Issue 12, 2016, Pages 1644-1655

  Eskilsson, Eskil ^a   Rosland, Gro V ^a   Talasila, Krishna M ^a   Knappskog, Stian ^a,b   Keunen, Olivier ^a,c   Sottoriva, Andrea ^c   Foerster, Sarah ^a   Solecki, Gergely ^f   Taxt, Torfinn ^d   Jirik, Radovan ^k   Fritah, Sabrina ^c,e   Harter, Patrick N ^h   Välk, Kristjan ^a   Al Hossain, Jubayer ^a,b   Joseph, Justin V ^a   Jahedi, Roza ^a,g   Saed, Halala S ^a   Piccirillo, Sara G ⁱ   Spiteri, Inma ^j   Euskirchen, Philipp ^k   Graziani, Grazia ^l   Daubon, Thomas ^a,m   Lund Johansen, Morten ^b   Enger, Per Øyvind ^a   Winkler, Frank ^f   Ritter, Christoph A ^e   Niclou, Simone P ^c   Watts, Colin ⁱ   Bjerkvig, Rolf ^a,c   Miletic, Hrvoje ^a,b   more..

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e UNIVERSITY OF GREIFSWALD   (Germany)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^g INSTITUTE OF SCIENTIFIC INSTRUMENTS   (Czech Republic)

^h GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

ⁱ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^j UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^k CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^l UNIVERSITY OF ROME TOR VERGATA   (Italy)

^m UNIVERSITÉ DE BORDEAUX   (France)

more..

Author keywords

Angiogenesis; EGFR; EGFRvIII; Glioblastoma; Invasion

Indexed keywords

PROTEIN TYROSINE KINASE; VASCULOTROPIN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; PROTEIN KINASE P60;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CLONAL EVOLUTION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GLIOBLASTOMA; GROWTH RATE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE; PROTEIN SECRETION; RAT; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; BRAIN; BRAIN TUMOR; DIAGNOSTIC IMAGING; GENETICS; METABOLISM; MOLECULAR EVOLUTION; MULTIMODAL IMAGING; MUTATION; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SURVIVAL ANALYSIS; TUMOR CELL LINE; TUMOR INVASION; UPREGULATION;

BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; EVOLUTION, MOLECULAR; GLIOBLASTOMA; HUMANS; MULTIMODAL IMAGING; MUTATION; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS PP60(C-SRC); RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; UP-REGULATION;

EID: 85006870204     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/now113     Document Type: Article

References (45)

1. Fuller GN, Bigner SH Amplified cellular oncogenes in neoplasms of the human central nervous system. Mutat Res. 1992; 276(3): 299-306.
2. Wong AJ, Ruppert JM, Bigner S.H., et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA. 1992; 89(7):2965-2969.
3. Wei Q, Clarke L, Scheidenhelm D.K., et al. High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. Cancer Res. 2006; 66(15):7429-7437.
4. Li L, Dutra A, Pak E., et al. EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors. Neuro Oncol. 2009; 11(1):9-21.
5. Meacham CE, Morrison SJ Tumour heterogeneity and cancer cell plasticity. Nature. 2013; 501(7467):328-337.
6. Bedard PL, Hansen AR, Ratain M.J., Siu LL. Tumour heterogeneity in the clinic. Nature. 2013; 501(7467):355-364.
7. Rosland GV, Engelsen AS Novel points of attack for targeted cancer therapy. Basic Clin Pharmacol Toxicol. 2014; 116(1):9-18.
8. Sottoriva A, Spiteri I, Piccirillo S.G., et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA. 2013; 110(10):4009-4014.
9. Patel AP, Tirosh I, Trombetta J.J., et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014; 344(6190):1396-1401.
10. Francis JM, Zhang CZ, Maire C.L., et al. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov. 2014; 4(8):956-971.
11. Pedersen MW, Tkach V, Pedersen N., Berezin V, Poulsen HS. Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility. Int J Cancer. 2004; 108(5):643-653.
12. Maity A, Pore N, Lee J., Solomon D, O'Rourke DM. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia. Cancer Res. 2000; 60(20): 5879-5886.
13. Magnus N, Garnier D, Rak J. Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. Blood. 2010; 116(5): 815-818.
14. Martens T, Laabs Y, Gunther H.S., et al. Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2. Clin Cancer Res. 2008; 14(17):5447-5458.
15. Guillamo JS, de Bouard S, Valable S, et al Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma. Clin Cancer Res. 2009; 15(11):3697-3704.
16. Bonavia R, Inda MM, Vandenberg S, et al EGFRvIII promotes glioma angiogenesis and growth through the NF-kB, interleukin-8 pathway. Oncogene. 2012; 31(36):4054-4066.
17. Clarke K, Smith K, Gullick W.J., Harris AL. Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway. Br J Cancer. 2001; 84(10):1322-1329.
18. Jin X, Yin J, Kim S.H., et al. EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction. Cancer Res. 2011; 71(22):7125-7134.
19. Feng H, Hu B, Vuori K., et al. EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180. Oncogene. 2013; 33(19):2504-2512.
20. Katanasaka Y, Kodera Y, Kitamura Y., Morimoto T, Tamura T, Koizumi F. Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma. Mol Cancer. 2013; 12:31.
21. Boockvar JA, Kapitonov D, Kapoor G., et al. Constitutive EGFR signaling confers a motile phenotype to neural stem cells. Mol Cell Neurosci. 2003; 24(4):1116-1130.
22. Nathanson DA, Gini B, Mottahedeh J., et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science. 2014; 343(6166):72-76.
23. Sakariassen PO, Prestegarden L, Wang J., et al. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci USA. 2006; 103(44):16466-16471.
24. Campos B, Wan F, Farhadi M., et al. Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin Cancer Res. 2010; 16(10):2715-2728.
25. Podergajs N, Brekka N, Radlwimmer B., et al. Expansive growth of two glioblastoma stem-like cell lines is mediated by bFGF and not by EGF. Radiol Oncol. 2013; 47(4):330-337.
26. Talasila KM, Soentgerath A, Euskirchen P., et al. EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis. Acta Neuropathol. 2013; 125(5):683-698.
27. Foerster S, Kacprowski T, Dhople V.M., et al. Characterization of the EGFR interactome reveals associated protein complex networks and intracellular receptor dynamics. Proteomics. 2013; 13(21): 3131-3144.
28. Huszthy PC, Giroglou T, Tsinkalovsky O., et al. Remission of invasive, cancer stem-like glioblastoma xenografts using lentiviral vector-mediated suicide gene therapy. PLoS One. 2009; 4(7):e6314.
29. Keunen O, Johansson M, Oudin A., et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA. 2011; 108(9):3749-3754.
30. Taxt T, Jirik R, Rygh C.B., et al. Single-channel blind estimation of arterial input function and tissue impulse response in DCE-MRI. IEEE Trans Biomed Eng. 2012; 59(4):1012-1021.
31. Sottoriva A, Spiteri I, Shibata D., Curtis C, Tavare S. Single-molecule genomic data delineate patient-specific tumor profiles and cancer stem cell organization. Cancer Res. 2013; 73(1):41-49.
32. Piccirillo SG, Spiteri I, Sottoriva A., et al. Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone. Cancer Res. 2014; 75(1):194-202.
33. Ji H, Wang J, Nika H., et al. EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin. Mol Cell. 2009; 36(4):547-559.
34. Glading A, Chang P, Lauffenburger D.A., Wells A. Epidermal growth factor receptor activation of calpain is required for fibroblast motility and occurs via an ERK/MAP kinase signaling pathway. J Biol Chem. 2000; 275(4):2390-2398.
35. Lu KV, Zhu S, Cvrljevic A., et al. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res. 2009; 69(17):6889-6898.
36. Thomas SM, Brugge JS Cellular functions regulated by Src family kinases. Ann Rev Cell Dev Bio. 1997; 13:513-609.
37. Angers-Loustau A., Hering R, Werbowetski T.E., Kaplan DR, Del Maestro RF. SRC regulates actin dynamics and invasion of malignant glial cells in three dimensions. Mol Cancer Res. 2004; 2(11):595-605.
38. Nishikawa R, Ji XD, Harmon R.C., et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA. 1994; 91(16):7727-7731.
39. Nagane M, Coufal F, Lin H., Bogler O, Cavenee WK, Huang HJ A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res. 1996; 56(21):5079-5086.
40. Tykocinski ES, Grant RA, Kapoor G.S., et al. Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma. Neuro Oncol. 2012; 14(5):613-623.
41. Cvrljevic AN, Akhavan D, Wu M., et al. Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism. J Cell Sci. 2011; 124(Pt 17):2938-2950.
42. Wiener JR, Nakano K, Kruzelock R.P., Bucana CD, Bast RC Jr, Gallick GE. Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model. Clin Cancer Res. 1999; 5(8):2164-2170.
43. Fleming RY, Ellis LM, Parikh N.U., Liu W., Staley CA, Gallick GE. Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by activity of src kinase. Surgery. 1997; 122(2):501-507.
44. Mukhopadhyay D, Tsiokas L, Zhou X-M, Foster D, Brugge J.S., Sukhatme VP. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature. 1995; 375(6532):577-581.
45. Huveldt D, Lewis-Tuffin LJ, Carlson B.L., et al. Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion. PLoS One. 2013; 8(2):e56505.